Why is this topic important?
- GLP-1 agonists are being used widely for weight loss, but establishing safety and efficacy in transplant is yet to be determined. It is important to understand the current practice/attitudes of transplant programs towards GLP-1 agonists and use in potential recipients and potential living donors. Establishing safe and acceptable practices in transplant to obtain and maintain goal weight during various phases of care will help improve transplant patient outcomes.
Speakers:
- Elizabeth Cohen, PharmD, BCPS, FAST • Senior Transplant Data Administrator, Yale New Haven Hospital, New Haven, CT
- Hyosun Han, MD, FAST • Associate Professor of Clinical Medicine, Keck School of Medicine of USC, Los Angeles, CA
- Anju Yadav, MD, FASN, FAST • Associate Professor, Johns Hopkins University, Baltimore, MD
Moderator:
- Sima Saberi, MD • Clinical Assistant Professor, University of Michigan, Ann Arbor, MI
Objectives:
- Describe the use of GLP-1 agonist to improve weight loss in transplant candidates including real world experiences in weight loss clinics
- Investigate the use of GLP-1 agonists to improve candidacy for living donors
- Address the management and safety of GLP-1 agonists once patients undergo transplant/donation (peri-operative and post-operative considerations) and goals to maintain weight loss in the long term
The AST Education Committee would like to thank AST's TxPharm COP, LDCOP, KPCOP, and PSECOP for suggesting this topic for the 2024-2025 T3 webinar series. Learn more about AST's COPs at www.myast.org/cops.
T3 webinars are $25.00 but free for AST members!